+Follow
JJ777
No personal profile
22
Follow
0
Followers
0
Topic
0
Badge
Posts
Hot
JJ777
2021-03-18
good
Moderna's Latest Move May be Key to COVID-19 Vaccine Market Dominance
JJ777
2021-03-18
good
2 Great Stocks You Can Buy on Sale
JJ777
2021-03-02
Ok
A Look Into Technology Sector Value Stocks
JJ777
2021-03-02
ok
Sorry, the original content has been removed
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3575925842692907","uuid":"3575925842692907","gmtCreate":1612835053072,"gmtModify":1614649759340,"name":"JJ777","pinyin":"jj777","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/01f75dc0b802594bbf8c5c22b48ab435","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":22,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.03.24","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":327806441,"gmtCreate":1616074792683,"gmtModify":1704790566553,"author":{"id":"3575925842692907","authorId":"3575925842692907","name":"JJ777","avatar":"https://static.tigerbbs.com/01f75dc0b802594bbf8c5c22b48ab435","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575925842692907","idStr":"3575925842692907"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/327806441","repostId":"1164556914","repostType":4,"repost":{"id":"1164556914","kind":"news","pubTimestamp":1616070336,"share":"https://ttm.financial/m/news/1164556914?lang=en_US&edition=fundamental","pubTime":"2021-03-18 20:25","market":"us","language":"en","title":"Moderna's Latest Move May be Key to COVID-19 Vaccine Market Dominance","url":"https://stock-news.laohu8.com/highlight/detail?id=1164556914","media":"Motley Fool","summary":"And it could mean at least another $1 billion in revenue for the biotech.\n\nModerna(NASDAQ:MRNA)may a","content":"<blockquote>\n <b>And it could mean at least another $1 billion in revenue for the biotech.</b>\n</blockquote>\n<p><b>Moderna</b>(NASDAQ:MRNA)may already seem like a market leader. The biotech company's COVID-19 vaccine was only the second to earn an emergency use authorization (EUA) from the Food and Drug Administration, shortly after<b>Pfizer</b>and partner<b>BioNTech</b>garnered one forBNT162b2. In the months since, the U.S. has administered more than 54 million doses of the Moderna vaccine alone. And the Biden administration signed additional deals to buy enough Moderna and Pfizer doses to vaccinate the entire U.S. population.</p>\n<p>But these companies are not yet able to cater to the whole potential market. The FDA has only authorized their vaccines -- and the recently approved<b>Johnson & Johnson</b>inoculation -- for use in adults.</p>\n<p>This week, however, Moderna became the first to launch a COVID-19 vaccine trial in children ages 6 months through 11 years old. And its speed here might give it a sales edge.</p>\n<p><b>The first EUAs</b></p>\n<p>The FDA granted the Moderna and Johnson & Johnson vaccines EUAs for people 18 and older, but authorized Pfizer's vaccine for those 16 and older. That's because Pfizer presented satisfactory trial data on participants in that slightly wider age range.</p>\n<p>Now, Moderna and Pfizer both are already studying their vaccines in teens. Both recently said their teen trials are fully enrolled. Moderna earlier said it's targeting a data readout this spring and vaccine deployment in time for autumn's back-to-school period. We might expect both companies to vie for this market at about the same time. Johnson & Johnson hasn't yet launched trials in the under-18 population. But it plans to do so, according to a<i>USA Today</i>report.</p>\n<p>When it comes to vaccinating an even younger population, it's clear Moderna has taken the lead from a timeline perspective. The biotech expects to vaccinate 6,750 healthy participants in the U.S. and Canada in its phase 2/3 pediatric study. The trial includes two parts. In part one, researchers will give participants ages 2 through 11 one of two possible doses ofmRNA-1273, while those who are younger will receive one of three possible doses. The data gleaned from that phase will determine the dosage to be used in the second part of the trial, which will include a vaccine group and a control group that will receive placebos.</p>\n<p>Moderna has not said how quickly it expects the study to generate results. But if all goes smoothly,mRNA-1273may be available to the pediatric market ahead of rivals. Being first to market almost always confers an advantage. If doctors and their patients are satisfied with the earliest arrival's safety profile and efficacy, they're likely to stick with it.</p>\n<p><b>What does this mean for Moderna's revenue?</b></p>\n<p>Let's do a little math. About 15% of the U.S. population is under 12, according to National Kids Count data. That's more than 48 million individuals. Using the price the federal government paid Moderna for itsmRNA-1273doses and considering a two-dose regimen, we can make a sales estimate. At $15 per dose for about 100 million doses to vaccinate children, Moderna would generate $1.5 billion in revenue in the U.S. market alone. And there's certainly room for it to grow revenue further by meeting the vaccine needs of younger populations in foreign markets.</p>\n<p>Though severe cases of COVID-19 are relatively rare in children, vaccinating the younger set will nonetheless be a key step in stemming the spread of coronavirus and ending the pandemic. It's not entirely clear yet the degree to which vaccination reduces the transmission of the virus by those who become infected despite having been inoculated. But fewer symptomatic infections may reduce viral shedding into the environment, which means fewer people would be exposed to COVID-19.</p>\n<p>Will Moderna be the first company able to vaccinate across all age groups? Clinical trial data will answer that question. But if it doesn't encounter any surprises, Moderna could win this stage of the race, giving it a leg up on its rivals.</p>\n<p>Of course, in this case, issues of supply and demand mean that such dominance can only take a company so far. Moderna's capacity to producemRNA-1273this year is expected to be between 700 million and 1 billion doses. That's not enough to vaccinate the whole world. It will take many companies to complete the task. So Pfizer, Johnson & Johnson, and other vaccine makers all stand to benefit.</p>\n<p>What this clinical trial news does mean is that Moderna investors have one more reason to be optimistic about thebiotech company-- and its abilityto increase its revenueover the long term.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna's Latest Move May be Key to COVID-19 Vaccine Market Dominance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna's Latest Move May be Key to COVID-19 Vaccine Market Dominance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-18 20:25 GMT+8 <a href=https://www.fool.com/investing/2021/03/18/modernas-latest-move-may-be-key-to-covid-19-vaccin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>And it could mean at least another $1 billion in revenue for the biotech.\n\nModerna(NASDAQ:MRNA)may already seem like a market leader. The biotech company's COVID-19 vaccine was only the second to earn...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/18/modernas-latest-move-may-be-key-to-covid-19-vaccin/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/03/18/modernas-latest-move-may-be-key-to-covid-19-vaccin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164556914","content_text":"And it could mean at least another $1 billion in revenue for the biotech.\n\nModerna(NASDAQ:MRNA)may already seem like a market leader. The biotech company's COVID-19 vaccine was only the second to earn an emergency use authorization (EUA) from the Food and Drug Administration, shortly afterPfizerand partnerBioNTechgarnered one forBNT162b2. In the months since, the U.S. has administered more than 54 million doses of the Moderna vaccine alone. And the Biden administration signed additional deals to buy enough Moderna and Pfizer doses to vaccinate the entire U.S. population.\nBut these companies are not yet able to cater to the whole potential market. The FDA has only authorized their vaccines -- and the recently approvedJohnson & Johnsoninoculation -- for use in adults.\nThis week, however, Moderna became the first to launch a COVID-19 vaccine trial in children ages 6 months through 11 years old. And its speed here might give it a sales edge.\nThe first EUAs\nThe FDA granted the Moderna and Johnson & Johnson vaccines EUAs for people 18 and older, but authorized Pfizer's vaccine for those 16 and older. That's because Pfizer presented satisfactory trial data on participants in that slightly wider age range.\nNow, Moderna and Pfizer both are already studying their vaccines in teens. Both recently said their teen trials are fully enrolled. Moderna earlier said it's targeting a data readout this spring and vaccine deployment in time for autumn's back-to-school period. We might expect both companies to vie for this market at about the same time. Johnson & Johnson hasn't yet launched trials in the under-18 population. But it plans to do so, according to aUSA Todayreport.\nWhen it comes to vaccinating an even younger population, it's clear Moderna has taken the lead from a timeline perspective. The biotech expects to vaccinate 6,750 healthy participants in the U.S. and Canada in its phase 2/3 pediatric study. The trial includes two parts. In part one, researchers will give participants ages 2 through 11 one of two possible doses ofmRNA-1273, while those who are younger will receive one of three possible doses. The data gleaned from that phase will determine the dosage to be used in the second part of the trial, which will include a vaccine group and a control group that will receive placebos.\nModerna has not said how quickly it expects the study to generate results. But if all goes smoothly,mRNA-1273may be available to the pediatric market ahead of rivals. Being first to market almost always confers an advantage. If doctors and their patients are satisfied with the earliest arrival's safety profile and efficacy, they're likely to stick with it.\nWhat does this mean for Moderna's revenue?\nLet's do a little math. About 15% of the U.S. population is under 12, according to National Kids Count data. That's more than 48 million individuals. Using the price the federal government paid Moderna for itsmRNA-1273doses and considering a two-dose regimen, we can make a sales estimate. At $15 per dose for about 100 million doses to vaccinate children, Moderna would generate $1.5 billion in revenue in the U.S. market alone. And there's certainly room for it to grow revenue further by meeting the vaccine needs of younger populations in foreign markets.\nThough severe cases of COVID-19 are relatively rare in children, vaccinating the younger set will nonetheless be a key step in stemming the spread of coronavirus and ending the pandemic. It's not entirely clear yet the degree to which vaccination reduces the transmission of the virus by those who become infected despite having been inoculated. But fewer symptomatic infections may reduce viral shedding into the environment, which means fewer people would be exposed to COVID-19.\nWill Moderna be the first company able to vaccinate across all age groups? Clinical trial data will answer that question. But if it doesn't encounter any surprises, Moderna could win this stage of the race, giving it a leg up on its rivals.\nOf course, in this case, issues of supply and demand mean that such dominance can only take a company so far. Moderna's capacity to producemRNA-1273this year is expected to be between 700 million and 1 billion doses. That's not enough to vaccinate the whole world. It will take many companies to complete the task. So Pfizer, Johnson & Johnson, and other vaccine makers all stand to benefit.\nWhat this clinical trial news does mean is that Moderna investors have one more reason to be optimistic about thebiotech company-- and its abilityto increase its revenueover the long term.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1296,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":327808154,"gmtCreate":1616074751078,"gmtModify":1704790564083,"author":{"id":"3575925842692907","authorId":"3575925842692907","name":"JJ777","avatar":"https://static.tigerbbs.com/01f75dc0b802594bbf8c5c22b48ab435","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575925842692907","idStr":"3575925842692907"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/327808154","repostId":"1190015090","repostType":4,"repost":{"id":"1190015090","kind":"news","pubTimestamp":1616070434,"share":"https://ttm.financial/m/news/1190015090?lang=en_US&edition=fundamental","pubTime":"2021-03-18 20:27","market":"us","language":"en","title":"2 Great Stocks You Can Buy on Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=1190015090","media":"Motley Fool","summary":"There aren't many deals out there right now, but these are two of the better ones you can snag.\n\nAs ","content":"<blockquote>\n <b>There aren't many deals out there right now, but these are two of the better ones you can snag.</b>\n</blockquote>\n<p>As the vaccine rollout ramps up, the end of coronavirus pandemic in just about in sight. In turn, investors have begun to focus more on a recovery and stocks that will be good buys once COVID-19 is a thing of the past. In the last month, shares of travel companies like<b>Boeing</b>and <b>Royal Caribbean</b>are up around 20%, while the<b>S&P 500</b>has been flat. For investors, that creates opportunities in other segments, as stocks that have done well amid the pandemic are falling out of favor and are now available at cheaper prices.</p>\n<p>Two stocks that are particularly attractive buys right now are<b>Zoom Video Communications</b>(NASDAQ:ZM)and<b>Regeneron Pharmaceuticals</b>(NASDAQ:REGN). They have been underperforming the markets lately, but their businesses still look to be in good shape, even if you expect the pandemic to come under control in the months ahead.</p>\n<p><b>1. Regeneron</b></p>\n<p>Regeneron's stock is down just 2.4% over the past month, but when looking at a six-month window, those declines reach 13% and are nearly a reverse image of the S&P 500's positive 16% gains during that period. Although Regeneron is far from just a COVID-19 stock, it rose in popularity last fall when former President Donald Trump was given its antibody cocktail, REGEN-COV2, when he contracted COVID.</p>\n<p>The U.S. Food and Drug Administration (FDA) has since issued an Emergency Use Authorization (EUA) for the cocktail to treat COVID-19, but that hasn't given the stock much of a lift. Although REGEN-COV2 did give the company's sales a boost of $185.7 million in 2020, that made up just 3.3% of total product sales of $5.6 billion.</p>\n<p>When the company reported its fourth-quarter earnings on Feb. 5, Regeneron's top line grew by 30% to $2.4 billion for the period ending Dec. 31, 2020. Sales from Eylea, its eye medication, rose by 10%. And the company's collaboration revenue from its partnerships with<b>Sanofi</b>and <b>Bayer</b>increased by more than 40%. Regeneron noted strong 56% sales growth in Dupixent, a monoclonal antibody that treats allergic diseases. The company shares in the profits on that product with Sanofi.</p>\n<p>Although Regeneron generated significant sales growth during the period, its operating expenses only grew by less than 6%, allowing much of that top-line growth to flow down into net income. The company's Q4 profits totaled $1.1 billion and rose 45% year over year.</p>\n<p>Whether you are worried about the pandemic or not, this is a solidhealthcare stockto put into your portfolio today. Currently, it is trading at aprice-to-earnings(P/E) multiple of less than 16, which is far below the average stock in the <b>Health Care Select Sector SPDR Fund</b>, which trades at more than 27 times its profits. Regeneron's multiple hasn't been this low since 2019.</p>\n<p><img src=\"https://static.tigerbbs.com/9402bbf2b4a9d70d3ddfe805c67c42ed\" tg-width=\"720\" tg-height=\"387\">2. Zoom</p>\n<p>Another stock that has benefitted from the our stay-at-home normal is video communications company, Zoom. The business thrived in 2020 in part because its easy-to-use videoconferencing service enabled companies and individuals to connect from home. With the click of a link, user can join a virtual meeting with hundreds of attendees within a matter of seconds.</p>\n<p>But when the pandemic ends, or at least when more people are back to being in the office, the need for Zoom's services could decline. That is what many investors may be worried about today -- especially for a stock that has more than tripled in value over the past year (while the S&P 500 has increased by 66%).</p>\n<p>Some of the bullishness around Zoom has certainly worn off. Zoom's stock has fallen by 25% over the past month. Its share price nearly fell below $300, a threshold it has been comfortably above since September of last year. Even a strong earnings report hasn't been enough to get the stock out of its funk.</p>\n<p>On March 1, Zoom released itsfourth-quarter numbers, and the company's sales and profits both came in better than analyst expectations. Its Q4 sales of $882.5 million for the period ending Jan. 31 were up an incredible 369% from the prior-year period. It finished the year with $2.65 billion in revenue, which is $2 billion more than it reported in the previous year.</p>\n<p>The company's bottom line may be the most impressive line item. At $56.1 million, GAAP income from operations for this past quarter was 2327% above the same 2019 metric.</p>\n<p>There is no doubt that Zoom has a tough act to follow this year, but the company still anticipates its sales to rise by 42%. The problem is that with a forward P/E ratio of just under 90, it is still an expensive buy with respect to its earnings (the average stock in the<b>Technology Select Sector SPDR Fund</b>trades at 34 times its profits).</p>\n<p>However, with high-growth stocks like Zoom, earnings numbers can change quickly. And although some investors are starting to look past the pandemic, there is still a lot of value here. As Zoom's sales start to slow down, it can give the company an opportunity to focus more on its expenses and making its operations more profitable.</p>\n<p>While shares of this top tech stock are down right now, investors shouldn't count Zoom out just yet. The need for virtual conference calls could remain strong this year and beyond, as pandemic-induced habits begin to stick around in the new normal.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Great Stocks You Can Buy on Sale</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Great Stocks You Can Buy on Sale\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-18 20:27 GMT+8 <a href=https://www.fool.com/investing/2021/03/18/2-great-stocks-you-can-buy-on-sale/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There aren't many deals out there right now, but these are two of the better ones you can snag.\n\nAs the vaccine rollout ramps up, the end of coronavirus pandemic in just about in sight. In turn, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/18/2-great-stocks-you-can-buy-on-sale/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","ZM":"Zoom"},"source_url":"https://www.fool.com/investing/2021/03/18/2-great-stocks-you-can-buy-on-sale/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190015090","content_text":"There aren't many deals out there right now, but these are two of the better ones you can snag.\n\nAs the vaccine rollout ramps up, the end of coronavirus pandemic in just about in sight. In turn, investors have begun to focus more on a recovery and stocks that will be good buys once COVID-19 is a thing of the past. In the last month, shares of travel companies likeBoeingand Royal Caribbeanare up around 20%, while theS&P 500has been flat. For investors, that creates opportunities in other segments, as stocks that have done well amid the pandemic are falling out of favor and are now available at cheaper prices.\nTwo stocks that are particularly attractive buys right now areZoom Video Communications(NASDAQ:ZM)andRegeneron Pharmaceuticals(NASDAQ:REGN). They have been underperforming the markets lately, but their businesses still look to be in good shape, even if you expect the pandemic to come under control in the months ahead.\n1. Regeneron\nRegeneron's stock is down just 2.4% over the past month, but when looking at a six-month window, those declines reach 13% and are nearly a reverse image of the S&P 500's positive 16% gains during that period. Although Regeneron is far from just a COVID-19 stock, it rose in popularity last fall when former President Donald Trump was given its antibody cocktail, REGEN-COV2, when he contracted COVID.\nThe U.S. Food and Drug Administration (FDA) has since issued an Emergency Use Authorization (EUA) for the cocktail to treat COVID-19, but that hasn't given the stock much of a lift. Although REGEN-COV2 did give the company's sales a boost of $185.7 million in 2020, that made up just 3.3% of total product sales of $5.6 billion.\nWhen the company reported its fourth-quarter earnings on Feb. 5, Regeneron's top line grew by 30% to $2.4 billion for the period ending Dec. 31, 2020. Sales from Eylea, its eye medication, rose by 10%. And the company's collaboration revenue from its partnerships withSanofiand Bayerincreased by more than 40%. Regeneron noted strong 56% sales growth in Dupixent, a monoclonal antibody that treats allergic diseases. The company shares in the profits on that product with Sanofi.\nAlthough Regeneron generated significant sales growth during the period, its operating expenses only grew by less than 6%, allowing much of that top-line growth to flow down into net income. The company's Q4 profits totaled $1.1 billion and rose 45% year over year.\nWhether you are worried about the pandemic or not, this is a solidhealthcare stockto put into your portfolio today. Currently, it is trading at aprice-to-earnings(P/E) multiple of less than 16, which is far below the average stock in the Health Care Select Sector SPDR Fund, which trades at more than 27 times its profits. Regeneron's multiple hasn't been this low since 2019.\n2. Zoom\nAnother stock that has benefitted from the our stay-at-home normal is video communications company, Zoom. The business thrived in 2020 in part because its easy-to-use videoconferencing service enabled companies and individuals to connect from home. With the click of a link, user can join a virtual meeting with hundreds of attendees within a matter of seconds.\nBut when the pandemic ends, or at least when more people are back to being in the office, the need for Zoom's services could decline. That is what many investors may be worried about today -- especially for a stock that has more than tripled in value over the past year (while the S&P 500 has increased by 66%).\nSome of the bullishness around Zoom has certainly worn off. Zoom's stock has fallen by 25% over the past month. Its share price nearly fell below $300, a threshold it has been comfortably above since September of last year. Even a strong earnings report hasn't been enough to get the stock out of its funk.\nOn March 1, Zoom released itsfourth-quarter numbers, and the company's sales and profits both came in better than analyst expectations. Its Q4 sales of $882.5 million for the period ending Jan. 31 were up an incredible 369% from the prior-year period. It finished the year with $2.65 billion in revenue, which is $2 billion more than it reported in the previous year.\nThe company's bottom line may be the most impressive line item. At $56.1 million, GAAP income from operations for this past quarter was 2327% above the same 2019 metric.\nThere is no doubt that Zoom has a tough act to follow this year, but the company still anticipates its sales to rise by 42%. The problem is that with a forward P/E ratio of just under 90, it is still an expensive buy with respect to its earnings (the average stock in theTechnology Select Sector SPDR Fundtrades at 34 times its profits).\nHowever, with high-growth stocks like Zoom, earnings numbers can change quickly. And although some investors are starting to look past the pandemic, there is still a lot of value here. As Zoom's sales start to slow down, it can give the company an opportunity to focus more on its expenses and making its operations more profitable.\nWhile shares of this top tech stock are down right now, investors shouldn't count Zoom out just yet. The need for virtual conference calls could remain strong this year and beyond, as pandemic-induced habits begin to stick around in the new normal.","news_type":1,"symbols_score_info":{"REGN":0.9,"ZM":0.9}},"isVote":1,"tweetType":1,"viewCount":1289,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":365378643,"gmtCreate":1614698871382,"gmtModify":1704774252575,"author":{"id":"3575925842692907","authorId":"3575925842692907","name":"JJ777","avatar":"https://static.tigerbbs.com/01f75dc0b802594bbf8c5c22b48ab435","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575925842692907","idStr":"3575925842692907"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/365378643","repostId":"2116999592","repostType":4,"repost":{"id":"2116999592","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1614697749,"share":"https://ttm.financial/m/news/2116999592?lang=en_US&edition=fundamental","pubTime":"2021-03-02 23:09","market":"hk","language":"en","title":"A Look Into Technology Sector Value Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2116999592","media":"Benzinga","summary":"The Meaning Behind Value Stocks\n\nA value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.","content":"<p><b>The Meaning Behind Value Stocks</b></p><p>A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.</p><p><b>Below is a list of notable value stocks in the technology sector:</b></p><ol><li><b>China Index Holdings</b> (NASDAQ:CIH) - P/E: 4.82</li><li><b>Nortech Systems</b> (NASDAQ:NSYS) - P/E: 8.96</li><li><b>Synnex</b> (NYSE:SNX) - P/E: 9.26</li><li><b><a href=\"https://laohu8.com/S/INPX\">Inpixon</a></b> (NASDAQ:INPX) - P/E: 0.08</li><li><b>Hamilton Beach Brands</b> (NYSE:HBB) - P/E: 8.75</li></ol><p>Most recently, China Index Holdings reported earnings per share at 0.12, whereas in Q2 earnings per share sat at 0.1. China Index Holdings does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.</p><p>Nortech Systems saw a decrease in earnings per share from -0.05 in Q2 to -0.35 now. Nortech Systems does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.</p><p>Most recently, Synnex reported earnings per share at 5.21, whereas in Q3 earnings per share sat at 3.33. The company's most recent dividend yield sits at 0.92%, which has decreased by 0.34% from 1.26% last quarter.</p><p>Most recently, Inpixon reported earnings per share at -0.13, whereas in Q2 earnings per share sat at -0.21. Inpixon does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.</p><p>Hamilton Beach Brands's earnings per share for Q3 sits at -0.15, whereas in Q2, they were at 0.59. Most recently, the company reported a dividend yield of 2.13%, which has increased by 0.18% from last quarter's yield of 1.95%.</p><p><b>The Significance:</b> A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look Into Technology Sector Value Stocks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look Into Technology Sector Value Stocks\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-03-02 23:09</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>The Meaning Behind Value Stocks</b></p><p>A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.</p><p><b>Below is a list of notable value stocks in the technology sector:</b></p><ol><li><b>China Index Holdings</b> (NASDAQ:CIH) - P/E: 4.82</li><li><b>Nortech Systems</b> (NASDAQ:NSYS) - P/E: 8.96</li><li><b>Synnex</b> (NYSE:SNX) - P/E: 9.26</li><li><b><a href=\"https://laohu8.com/S/INPX\">Inpixon</a></b> (NASDAQ:INPX) - P/E: 0.08</li><li><b>Hamilton Beach Brands</b> (NYSE:HBB) - P/E: 8.75</li></ol><p>Most recently, China Index Holdings reported earnings per share at 0.12, whereas in Q2 earnings per share sat at 0.1. China Index Holdings does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.</p><p>Nortech Systems saw a decrease in earnings per share from -0.05 in Q2 to -0.35 now. Nortech Systems does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.</p><p>Most recently, Synnex reported earnings per share at 5.21, whereas in Q3 earnings per share sat at 3.33. The company's most recent dividend yield sits at 0.92%, which has decreased by 0.34% from 1.26% last quarter.</p><p>Most recently, Inpixon reported earnings per share at -0.13, whereas in Q2 earnings per share sat at -0.21. Inpixon does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.</p><p>Hamilton Beach Brands's earnings per share for Q3 sits at -0.15, whereas in Q2, they were at 0.59. Most recently, the company reported a dividend yield of 2.13%, which has increased by 0.18% from last quarter's yield of 1.95%.</p><p><b>The Significance:</b> A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HBB":"Hamilton Beach Brands Holding Company","NSYS":"Nortech Systems Incorporated","SNX":"新聚思"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2116999592","content_text":"The Meaning Behind Value StocksA value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.Below is a list of notable value stocks in the technology sector:China Index Holdings (NASDAQ:CIH) - P/E: 4.82Nortech Systems (NASDAQ:NSYS) - P/E: 8.96Synnex (NYSE:SNX) - P/E: 9.26Inpixon (NASDAQ:INPX) - P/E: 0.08Hamilton Beach Brands (NYSE:HBB) - P/E: 8.75Most recently, China Index Holdings reported earnings per share at 0.12, whereas in Q2 earnings per share sat at 0.1. China Index Holdings does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Nortech Systems saw a decrease in earnings per share from -0.05 in Q2 to -0.35 now. Nortech Systems does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Most recently, Synnex reported earnings per share at 5.21, whereas in Q3 earnings per share sat at 3.33. The company's most recent dividend yield sits at 0.92%, which has decreased by 0.34% from 1.26% last quarter.Most recently, Inpixon reported earnings per share at -0.13, whereas in Q2 earnings per share sat at -0.21. Inpixon does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Hamilton Beach Brands's earnings per share for Q3 sits at -0.15, whereas in Q2, they were at 0.59. Most recently, the company reported a dividend yield of 2.13%, which has increased by 0.18% from last quarter's yield of 1.95%.The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.","news_type":1,"symbols_score_info":{"SNX":0.9,"CIH":0.9,"NSYS":0.9,"INPX":0.9,"HBB":0.9}},"isVote":1,"tweetType":1,"viewCount":846,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":362602852,"gmtCreate":1614616334676,"gmtModify":1704773199688,"author":{"id":"3575925842692907","authorId":"3575925842692907","name":"JJ777","avatar":"https://static.tigerbbs.com/01f75dc0b802594bbf8c5c22b48ab435","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575925842692907","idStr":"3575925842692907"},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/362602852","repostId":"2116855690","repostType":4,"isVote":1,"tweetType":1,"viewCount":1067,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":327806441,"gmtCreate":1616074792683,"gmtModify":1704790566553,"author":{"id":"3575925842692907","authorId":"3575925842692907","name":"JJ777","avatar":"https://static.tigerbbs.com/01f75dc0b802594bbf8c5c22b48ab435","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575925842692907","idStr":"3575925842692907"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/327806441","repostId":"1164556914","repostType":4,"repost":{"id":"1164556914","kind":"news","pubTimestamp":1616070336,"share":"https://ttm.financial/m/news/1164556914?lang=en_US&edition=fundamental","pubTime":"2021-03-18 20:25","market":"us","language":"en","title":"Moderna's Latest Move May be Key to COVID-19 Vaccine Market Dominance","url":"https://stock-news.laohu8.com/highlight/detail?id=1164556914","media":"Motley Fool","summary":"And it could mean at least another $1 billion in revenue for the biotech.\n\nModerna(NASDAQ:MRNA)may a","content":"<blockquote>\n <b>And it could mean at least another $1 billion in revenue for the biotech.</b>\n</blockquote>\n<p><b>Moderna</b>(NASDAQ:MRNA)may already seem like a market leader. The biotech company's COVID-19 vaccine was only the second to earn an emergency use authorization (EUA) from the Food and Drug Administration, shortly after<b>Pfizer</b>and partner<b>BioNTech</b>garnered one forBNT162b2. In the months since, the U.S. has administered more than 54 million doses of the Moderna vaccine alone. And the Biden administration signed additional deals to buy enough Moderna and Pfizer doses to vaccinate the entire U.S. population.</p>\n<p>But these companies are not yet able to cater to the whole potential market. The FDA has only authorized their vaccines -- and the recently approved<b>Johnson & Johnson</b>inoculation -- for use in adults.</p>\n<p>This week, however, Moderna became the first to launch a COVID-19 vaccine trial in children ages 6 months through 11 years old. And its speed here might give it a sales edge.</p>\n<p><b>The first EUAs</b></p>\n<p>The FDA granted the Moderna and Johnson & Johnson vaccines EUAs for people 18 and older, but authorized Pfizer's vaccine for those 16 and older. That's because Pfizer presented satisfactory trial data on participants in that slightly wider age range.</p>\n<p>Now, Moderna and Pfizer both are already studying their vaccines in teens. Both recently said their teen trials are fully enrolled. Moderna earlier said it's targeting a data readout this spring and vaccine deployment in time for autumn's back-to-school period. We might expect both companies to vie for this market at about the same time. Johnson & Johnson hasn't yet launched trials in the under-18 population. But it plans to do so, according to a<i>USA Today</i>report.</p>\n<p>When it comes to vaccinating an even younger population, it's clear Moderna has taken the lead from a timeline perspective. The biotech expects to vaccinate 6,750 healthy participants in the U.S. and Canada in its phase 2/3 pediatric study. The trial includes two parts. In part one, researchers will give participants ages 2 through 11 one of two possible doses ofmRNA-1273, while those who are younger will receive one of three possible doses. The data gleaned from that phase will determine the dosage to be used in the second part of the trial, which will include a vaccine group and a control group that will receive placebos.</p>\n<p>Moderna has not said how quickly it expects the study to generate results. But if all goes smoothly,mRNA-1273may be available to the pediatric market ahead of rivals. Being first to market almost always confers an advantage. If doctors and their patients are satisfied with the earliest arrival's safety profile and efficacy, they're likely to stick with it.</p>\n<p><b>What does this mean for Moderna's revenue?</b></p>\n<p>Let's do a little math. About 15% of the U.S. population is under 12, according to National Kids Count data. That's more than 48 million individuals. Using the price the federal government paid Moderna for itsmRNA-1273doses and considering a two-dose regimen, we can make a sales estimate. At $15 per dose for about 100 million doses to vaccinate children, Moderna would generate $1.5 billion in revenue in the U.S. market alone. And there's certainly room for it to grow revenue further by meeting the vaccine needs of younger populations in foreign markets.</p>\n<p>Though severe cases of COVID-19 are relatively rare in children, vaccinating the younger set will nonetheless be a key step in stemming the spread of coronavirus and ending the pandemic. It's not entirely clear yet the degree to which vaccination reduces the transmission of the virus by those who become infected despite having been inoculated. But fewer symptomatic infections may reduce viral shedding into the environment, which means fewer people would be exposed to COVID-19.</p>\n<p>Will Moderna be the first company able to vaccinate across all age groups? Clinical trial data will answer that question. But if it doesn't encounter any surprises, Moderna could win this stage of the race, giving it a leg up on its rivals.</p>\n<p>Of course, in this case, issues of supply and demand mean that such dominance can only take a company so far. Moderna's capacity to producemRNA-1273this year is expected to be between 700 million and 1 billion doses. That's not enough to vaccinate the whole world. It will take many companies to complete the task. So Pfizer, Johnson & Johnson, and other vaccine makers all stand to benefit.</p>\n<p>What this clinical trial news does mean is that Moderna investors have one more reason to be optimistic about thebiotech company-- and its abilityto increase its revenueover the long term.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna's Latest Move May be Key to COVID-19 Vaccine Market Dominance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna's Latest Move May be Key to COVID-19 Vaccine Market Dominance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-18 20:25 GMT+8 <a href=https://www.fool.com/investing/2021/03/18/modernas-latest-move-may-be-key-to-covid-19-vaccin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>And it could mean at least another $1 billion in revenue for the biotech.\n\nModerna(NASDAQ:MRNA)may already seem like a market leader. The biotech company's COVID-19 vaccine was only the second to earn...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/18/modernas-latest-move-may-be-key-to-covid-19-vaccin/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/03/18/modernas-latest-move-may-be-key-to-covid-19-vaccin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164556914","content_text":"And it could mean at least another $1 billion in revenue for the biotech.\n\nModerna(NASDAQ:MRNA)may already seem like a market leader. The biotech company's COVID-19 vaccine was only the second to earn an emergency use authorization (EUA) from the Food and Drug Administration, shortly afterPfizerand partnerBioNTechgarnered one forBNT162b2. In the months since, the U.S. has administered more than 54 million doses of the Moderna vaccine alone. And the Biden administration signed additional deals to buy enough Moderna and Pfizer doses to vaccinate the entire U.S. population.\nBut these companies are not yet able to cater to the whole potential market. The FDA has only authorized their vaccines -- and the recently approvedJohnson & Johnsoninoculation -- for use in adults.\nThis week, however, Moderna became the first to launch a COVID-19 vaccine trial in children ages 6 months through 11 years old. And its speed here might give it a sales edge.\nThe first EUAs\nThe FDA granted the Moderna and Johnson & Johnson vaccines EUAs for people 18 and older, but authorized Pfizer's vaccine for those 16 and older. That's because Pfizer presented satisfactory trial data on participants in that slightly wider age range.\nNow, Moderna and Pfizer both are already studying their vaccines in teens. Both recently said their teen trials are fully enrolled. Moderna earlier said it's targeting a data readout this spring and vaccine deployment in time for autumn's back-to-school period. We might expect both companies to vie for this market at about the same time. Johnson & Johnson hasn't yet launched trials in the under-18 population. But it plans to do so, according to aUSA Todayreport.\nWhen it comes to vaccinating an even younger population, it's clear Moderna has taken the lead from a timeline perspective. The biotech expects to vaccinate 6,750 healthy participants in the U.S. and Canada in its phase 2/3 pediatric study. The trial includes two parts. In part one, researchers will give participants ages 2 through 11 one of two possible doses ofmRNA-1273, while those who are younger will receive one of three possible doses. The data gleaned from that phase will determine the dosage to be used in the second part of the trial, which will include a vaccine group and a control group that will receive placebos.\nModerna has not said how quickly it expects the study to generate results. But if all goes smoothly,mRNA-1273may be available to the pediatric market ahead of rivals. Being first to market almost always confers an advantage. If doctors and their patients are satisfied with the earliest arrival's safety profile and efficacy, they're likely to stick with it.\nWhat does this mean for Moderna's revenue?\nLet's do a little math. About 15% of the U.S. population is under 12, according to National Kids Count data. That's more than 48 million individuals. Using the price the federal government paid Moderna for itsmRNA-1273doses and considering a two-dose regimen, we can make a sales estimate. At $15 per dose for about 100 million doses to vaccinate children, Moderna would generate $1.5 billion in revenue in the U.S. market alone. And there's certainly room for it to grow revenue further by meeting the vaccine needs of younger populations in foreign markets.\nThough severe cases of COVID-19 are relatively rare in children, vaccinating the younger set will nonetheless be a key step in stemming the spread of coronavirus and ending the pandemic. It's not entirely clear yet the degree to which vaccination reduces the transmission of the virus by those who become infected despite having been inoculated. But fewer symptomatic infections may reduce viral shedding into the environment, which means fewer people would be exposed to COVID-19.\nWill Moderna be the first company able to vaccinate across all age groups? Clinical trial data will answer that question. But if it doesn't encounter any surprises, Moderna could win this stage of the race, giving it a leg up on its rivals.\nOf course, in this case, issues of supply and demand mean that such dominance can only take a company so far. Moderna's capacity to producemRNA-1273this year is expected to be between 700 million and 1 billion doses. That's not enough to vaccinate the whole world. It will take many companies to complete the task. So Pfizer, Johnson & Johnson, and other vaccine makers all stand to benefit.\nWhat this clinical trial news does mean is that Moderna investors have one more reason to be optimistic about thebiotech company-- and its abilityto increase its revenueover the long term.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1296,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":365378643,"gmtCreate":1614698871382,"gmtModify":1704774252575,"author":{"id":"3575925842692907","authorId":"3575925842692907","name":"JJ777","avatar":"https://static.tigerbbs.com/01f75dc0b802594bbf8c5c22b48ab435","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575925842692907","idStr":"3575925842692907"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/365378643","repostId":"2116999592","repostType":4,"repost":{"id":"2116999592","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1614697749,"share":"https://ttm.financial/m/news/2116999592?lang=en_US&edition=fundamental","pubTime":"2021-03-02 23:09","market":"hk","language":"en","title":"A Look Into Technology Sector Value Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2116999592","media":"Benzinga","summary":"The Meaning Behind Value Stocks\n\nA value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.","content":"<p><b>The Meaning Behind Value Stocks</b></p><p>A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.</p><p><b>Below is a list of notable value stocks in the technology sector:</b></p><ol><li><b>China Index Holdings</b> (NASDAQ:CIH) - P/E: 4.82</li><li><b>Nortech Systems</b> (NASDAQ:NSYS) - P/E: 8.96</li><li><b>Synnex</b> (NYSE:SNX) - P/E: 9.26</li><li><b><a href=\"https://laohu8.com/S/INPX\">Inpixon</a></b> (NASDAQ:INPX) - P/E: 0.08</li><li><b>Hamilton Beach Brands</b> (NYSE:HBB) - P/E: 8.75</li></ol><p>Most recently, China Index Holdings reported earnings per share at 0.12, whereas in Q2 earnings per share sat at 0.1. China Index Holdings does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.</p><p>Nortech Systems saw a decrease in earnings per share from -0.05 in Q2 to -0.35 now. Nortech Systems does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.</p><p>Most recently, Synnex reported earnings per share at 5.21, whereas in Q3 earnings per share sat at 3.33. The company's most recent dividend yield sits at 0.92%, which has decreased by 0.34% from 1.26% last quarter.</p><p>Most recently, Inpixon reported earnings per share at -0.13, whereas in Q2 earnings per share sat at -0.21. Inpixon does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.</p><p>Hamilton Beach Brands's earnings per share for Q3 sits at -0.15, whereas in Q2, they were at 0.59. Most recently, the company reported a dividend yield of 2.13%, which has increased by 0.18% from last quarter's yield of 1.95%.</p><p><b>The Significance:</b> A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look Into Technology Sector Value Stocks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look Into Technology Sector Value Stocks\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-03-02 23:09</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>The Meaning Behind Value Stocks</b></p><p>A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.</p><p><b>Below is a list of notable value stocks in the technology sector:</b></p><ol><li><b>China Index Holdings</b> (NASDAQ:CIH) - P/E: 4.82</li><li><b>Nortech Systems</b> (NASDAQ:NSYS) - P/E: 8.96</li><li><b>Synnex</b> (NYSE:SNX) - P/E: 9.26</li><li><b><a href=\"https://laohu8.com/S/INPX\">Inpixon</a></b> (NASDAQ:INPX) - P/E: 0.08</li><li><b>Hamilton Beach Brands</b> (NYSE:HBB) - P/E: 8.75</li></ol><p>Most recently, China Index Holdings reported earnings per share at 0.12, whereas in Q2 earnings per share sat at 0.1. China Index Holdings does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.</p><p>Nortech Systems saw a decrease in earnings per share from -0.05 in Q2 to -0.35 now. Nortech Systems does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.</p><p>Most recently, Synnex reported earnings per share at 5.21, whereas in Q3 earnings per share sat at 3.33. The company's most recent dividend yield sits at 0.92%, which has decreased by 0.34% from 1.26% last quarter.</p><p>Most recently, Inpixon reported earnings per share at -0.13, whereas in Q2 earnings per share sat at -0.21. Inpixon does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.</p><p>Hamilton Beach Brands's earnings per share for Q3 sits at -0.15, whereas in Q2, they were at 0.59. Most recently, the company reported a dividend yield of 2.13%, which has increased by 0.18% from last quarter's yield of 1.95%.</p><p><b>The Significance:</b> A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HBB":"Hamilton Beach Brands Holding Company","NSYS":"Nortech Systems Incorporated","SNX":"新聚思"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2116999592","content_text":"The Meaning Behind Value StocksA value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.Below is a list of notable value stocks in the technology sector:China Index Holdings (NASDAQ:CIH) - P/E: 4.82Nortech Systems (NASDAQ:NSYS) - P/E: 8.96Synnex (NYSE:SNX) - P/E: 9.26Inpixon (NASDAQ:INPX) - P/E: 0.08Hamilton Beach Brands (NYSE:HBB) - P/E: 8.75Most recently, China Index Holdings reported earnings per share at 0.12, whereas in Q2 earnings per share sat at 0.1. China Index Holdings does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Nortech Systems saw a decrease in earnings per share from -0.05 in Q2 to -0.35 now. Nortech Systems does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Most recently, Synnex reported earnings per share at 5.21, whereas in Q3 earnings per share sat at 3.33. The company's most recent dividend yield sits at 0.92%, which has decreased by 0.34% from 1.26% last quarter.Most recently, Inpixon reported earnings per share at -0.13, whereas in Q2 earnings per share sat at -0.21. Inpixon does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Hamilton Beach Brands's earnings per share for Q3 sits at -0.15, whereas in Q2, they were at 0.59. Most recently, the company reported a dividend yield of 2.13%, which has increased by 0.18% from last quarter's yield of 1.95%.The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.","news_type":1,"symbols_score_info":{"SNX":0.9,"CIH":0.9,"NSYS":0.9,"INPX":0.9,"HBB":0.9}},"isVote":1,"tweetType":1,"viewCount":846,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":327808154,"gmtCreate":1616074751078,"gmtModify":1704790564083,"author":{"id":"3575925842692907","authorId":"3575925842692907","name":"JJ777","avatar":"https://static.tigerbbs.com/01f75dc0b802594bbf8c5c22b48ab435","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575925842692907","idStr":"3575925842692907"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/327808154","repostId":"1190015090","repostType":4,"repost":{"id":"1190015090","kind":"news","pubTimestamp":1616070434,"share":"https://ttm.financial/m/news/1190015090?lang=en_US&edition=fundamental","pubTime":"2021-03-18 20:27","market":"us","language":"en","title":"2 Great Stocks You Can Buy on Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=1190015090","media":"Motley Fool","summary":"There aren't many deals out there right now, but these are two of the better ones you can snag.\n\nAs ","content":"<blockquote>\n <b>There aren't many deals out there right now, but these are two of the better ones you can snag.</b>\n</blockquote>\n<p>As the vaccine rollout ramps up, the end of coronavirus pandemic in just about in sight. In turn, investors have begun to focus more on a recovery and stocks that will be good buys once COVID-19 is a thing of the past. In the last month, shares of travel companies like<b>Boeing</b>and <b>Royal Caribbean</b>are up around 20%, while the<b>S&P 500</b>has been flat. For investors, that creates opportunities in other segments, as stocks that have done well amid the pandemic are falling out of favor and are now available at cheaper prices.</p>\n<p>Two stocks that are particularly attractive buys right now are<b>Zoom Video Communications</b>(NASDAQ:ZM)and<b>Regeneron Pharmaceuticals</b>(NASDAQ:REGN). They have been underperforming the markets lately, but their businesses still look to be in good shape, even if you expect the pandemic to come under control in the months ahead.</p>\n<p><b>1. Regeneron</b></p>\n<p>Regeneron's stock is down just 2.4% over the past month, but when looking at a six-month window, those declines reach 13% and are nearly a reverse image of the S&P 500's positive 16% gains during that period. Although Regeneron is far from just a COVID-19 stock, it rose in popularity last fall when former President Donald Trump was given its antibody cocktail, REGEN-COV2, when he contracted COVID.</p>\n<p>The U.S. Food and Drug Administration (FDA) has since issued an Emergency Use Authorization (EUA) for the cocktail to treat COVID-19, but that hasn't given the stock much of a lift. Although REGEN-COV2 did give the company's sales a boost of $185.7 million in 2020, that made up just 3.3% of total product sales of $5.6 billion.</p>\n<p>When the company reported its fourth-quarter earnings on Feb. 5, Regeneron's top line grew by 30% to $2.4 billion for the period ending Dec. 31, 2020. Sales from Eylea, its eye medication, rose by 10%. And the company's collaboration revenue from its partnerships with<b>Sanofi</b>and <b>Bayer</b>increased by more than 40%. Regeneron noted strong 56% sales growth in Dupixent, a monoclonal antibody that treats allergic diseases. The company shares in the profits on that product with Sanofi.</p>\n<p>Although Regeneron generated significant sales growth during the period, its operating expenses only grew by less than 6%, allowing much of that top-line growth to flow down into net income. The company's Q4 profits totaled $1.1 billion and rose 45% year over year.</p>\n<p>Whether you are worried about the pandemic or not, this is a solidhealthcare stockto put into your portfolio today. Currently, it is trading at aprice-to-earnings(P/E) multiple of less than 16, which is far below the average stock in the <b>Health Care Select Sector SPDR Fund</b>, which trades at more than 27 times its profits. Regeneron's multiple hasn't been this low since 2019.</p>\n<p><img src=\"https://static.tigerbbs.com/9402bbf2b4a9d70d3ddfe805c67c42ed\" tg-width=\"720\" tg-height=\"387\">2. Zoom</p>\n<p>Another stock that has benefitted from the our stay-at-home normal is video communications company, Zoom. The business thrived in 2020 in part because its easy-to-use videoconferencing service enabled companies and individuals to connect from home. With the click of a link, user can join a virtual meeting with hundreds of attendees within a matter of seconds.</p>\n<p>But when the pandemic ends, or at least when more people are back to being in the office, the need for Zoom's services could decline. That is what many investors may be worried about today -- especially for a stock that has more than tripled in value over the past year (while the S&P 500 has increased by 66%).</p>\n<p>Some of the bullishness around Zoom has certainly worn off. Zoom's stock has fallen by 25% over the past month. Its share price nearly fell below $300, a threshold it has been comfortably above since September of last year. Even a strong earnings report hasn't been enough to get the stock out of its funk.</p>\n<p>On March 1, Zoom released itsfourth-quarter numbers, and the company's sales and profits both came in better than analyst expectations. Its Q4 sales of $882.5 million for the period ending Jan. 31 were up an incredible 369% from the prior-year period. It finished the year with $2.65 billion in revenue, which is $2 billion more than it reported in the previous year.</p>\n<p>The company's bottom line may be the most impressive line item. At $56.1 million, GAAP income from operations for this past quarter was 2327% above the same 2019 metric.</p>\n<p>There is no doubt that Zoom has a tough act to follow this year, but the company still anticipates its sales to rise by 42%. The problem is that with a forward P/E ratio of just under 90, it is still an expensive buy with respect to its earnings (the average stock in the<b>Technology Select Sector SPDR Fund</b>trades at 34 times its profits).</p>\n<p>However, with high-growth stocks like Zoom, earnings numbers can change quickly. And although some investors are starting to look past the pandemic, there is still a lot of value here. As Zoom's sales start to slow down, it can give the company an opportunity to focus more on its expenses and making its operations more profitable.</p>\n<p>While shares of this top tech stock are down right now, investors shouldn't count Zoom out just yet. The need for virtual conference calls could remain strong this year and beyond, as pandemic-induced habits begin to stick around in the new normal.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Great Stocks You Can Buy on Sale</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Great Stocks You Can Buy on Sale\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-18 20:27 GMT+8 <a href=https://www.fool.com/investing/2021/03/18/2-great-stocks-you-can-buy-on-sale/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There aren't many deals out there right now, but these are two of the better ones you can snag.\n\nAs the vaccine rollout ramps up, the end of coronavirus pandemic in just about in sight. In turn, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/18/2-great-stocks-you-can-buy-on-sale/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司","ZM":"Zoom"},"source_url":"https://www.fool.com/investing/2021/03/18/2-great-stocks-you-can-buy-on-sale/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190015090","content_text":"There aren't many deals out there right now, but these are two of the better ones you can snag.\n\nAs the vaccine rollout ramps up, the end of coronavirus pandemic in just about in sight. In turn, investors have begun to focus more on a recovery and stocks that will be good buys once COVID-19 is a thing of the past. In the last month, shares of travel companies likeBoeingand Royal Caribbeanare up around 20%, while theS&P 500has been flat. For investors, that creates opportunities in other segments, as stocks that have done well amid the pandemic are falling out of favor and are now available at cheaper prices.\nTwo stocks that are particularly attractive buys right now areZoom Video Communications(NASDAQ:ZM)andRegeneron Pharmaceuticals(NASDAQ:REGN). They have been underperforming the markets lately, but their businesses still look to be in good shape, even if you expect the pandemic to come under control in the months ahead.\n1. Regeneron\nRegeneron's stock is down just 2.4% over the past month, but when looking at a six-month window, those declines reach 13% and are nearly a reverse image of the S&P 500's positive 16% gains during that period. Although Regeneron is far from just a COVID-19 stock, it rose in popularity last fall when former President Donald Trump was given its antibody cocktail, REGEN-COV2, when he contracted COVID.\nThe U.S. Food and Drug Administration (FDA) has since issued an Emergency Use Authorization (EUA) for the cocktail to treat COVID-19, but that hasn't given the stock much of a lift. Although REGEN-COV2 did give the company's sales a boost of $185.7 million in 2020, that made up just 3.3% of total product sales of $5.6 billion.\nWhen the company reported its fourth-quarter earnings on Feb. 5, Regeneron's top line grew by 30% to $2.4 billion for the period ending Dec. 31, 2020. Sales from Eylea, its eye medication, rose by 10%. And the company's collaboration revenue from its partnerships withSanofiand Bayerincreased by more than 40%. Regeneron noted strong 56% sales growth in Dupixent, a monoclonal antibody that treats allergic diseases. The company shares in the profits on that product with Sanofi.\nAlthough Regeneron generated significant sales growth during the period, its operating expenses only grew by less than 6%, allowing much of that top-line growth to flow down into net income. The company's Q4 profits totaled $1.1 billion and rose 45% year over year.\nWhether you are worried about the pandemic or not, this is a solidhealthcare stockto put into your portfolio today. Currently, it is trading at aprice-to-earnings(P/E) multiple of less than 16, which is far below the average stock in the Health Care Select Sector SPDR Fund, which trades at more than 27 times its profits. Regeneron's multiple hasn't been this low since 2019.\n2. Zoom\nAnother stock that has benefitted from the our stay-at-home normal is video communications company, Zoom. The business thrived in 2020 in part because its easy-to-use videoconferencing service enabled companies and individuals to connect from home. With the click of a link, user can join a virtual meeting with hundreds of attendees within a matter of seconds.\nBut when the pandemic ends, or at least when more people are back to being in the office, the need for Zoom's services could decline. That is what many investors may be worried about today -- especially for a stock that has more than tripled in value over the past year (while the S&P 500 has increased by 66%).\nSome of the bullishness around Zoom has certainly worn off. Zoom's stock has fallen by 25% over the past month. Its share price nearly fell below $300, a threshold it has been comfortably above since September of last year. Even a strong earnings report hasn't been enough to get the stock out of its funk.\nOn March 1, Zoom released itsfourth-quarter numbers, and the company's sales and profits both came in better than analyst expectations. Its Q4 sales of $882.5 million for the period ending Jan. 31 were up an incredible 369% from the prior-year period. It finished the year with $2.65 billion in revenue, which is $2 billion more than it reported in the previous year.\nThe company's bottom line may be the most impressive line item. At $56.1 million, GAAP income from operations for this past quarter was 2327% above the same 2019 metric.\nThere is no doubt that Zoom has a tough act to follow this year, but the company still anticipates its sales to rise by 42%. The problem is that with a forward P/E ratio of just under 90, it is still an expensive buy with respect to its earnings (the average stock in theTechnology Select Sector SPDR Fundtrades at 34 times its profits).\nHowever, with high-growth stocks like Zoom, earnings numbers can change quickly. And although some investors are starting to look past the pandemic, there is still a lot of value here. As Zoom's sales start to slow down, it can give the company an opportunity to focus more on its expenses and making its operations more profitable.\nWhile shares of this top tech stock are down right now, investors shouldn't count Zoom out just yet. The need for virtual conference calls could remain strong this year and beyond, as pandemic-induced habits begin to stick around in the new normal.","news_type":1,"symbols_score_info":{"REGN":0.9,"ZM":0.9}},"isVote":1,"tweetType":1,"viewCount":1289,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":362602852,"gmtCreate":1614616334676,"gmtModify":1704773199688,"author":{"id":"3575925842692907","authorId":"3575925842692907","name":"JJ777","avatar":"https://static.tigerbbs.com/01f75dc0b802594bbf8c5c22b48ab435","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575925842692907","idStr":"3575925842692907"},"themes":[],"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/362602852","repostId":"2116855690","repostType":4,"isVote":1,"tweetType":1,"viewCount":1067,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
